---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000056"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:53:49.440383+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q1 cash $1.17B, licenses ARV-766 to Novartis for $150M upfront

## Summary
- Q1 2024 revenue $25.3M, down from $32.5M YoY; R&D expenses $84.3M vs $95.3M YoY.
- Cash, equivalents and marketable securities $1,174.8M as of March 31, down $91.7M from year-end.
- Licensed ARV-766 to Novartis for $150M upfront, up to $1.01B in milestones plus royalties.
- Top-line data for vepdegestrant Phase 3 VERITAC-2 trial on track for 2H 2024.
- Phase 1 trial initiated for ARV-102 (LRRK2 degrader) in neurodegenerative diseases.

## SEC filing metadata
- accession: 0001655759-24-000056
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/0001655759-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/arvn-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000056
- JSON: https://secwatch.observer/filing/0001655759-24-000056.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000056.txt

## Key facts
- Earnings Releases
  ARVINAS, INC. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024 , Arvinas, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/0001655759-24-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.